Farmas USA

Auténtica crack

Yo la espero a que tenga las tipicas sesiones en las que la controlan al milimetro, ahi es cuando entrare en SNTA.

Enorme Ana! I love you!
Copiada a mi dropbox :)

Por si alguien no lo tiene y le interesa, os recuerdo el enlace a mi carpeta farmas USA en dropbox, cuyos contenidos intento ir actualizado a medida que salen novedades...

Un saludo

https://www.dropbox.com/sh/fgbdb5q1c0cgepz/u0n7mcTeB0

NW BIO ANNOUNCES ABOVE-MARKET CONVERSION OF ITS
$11.6 MILLION DEBT TO ITS MANUFACTURER, COGNATE BIOSERVICES
Conversion Shares Also Subject To 18-Month Lock-Up Agreement
BETHESDA, MD, July 31, 2013 -- Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a
biotechnology company developing non-toxic DCVax®
personalized immune therapies for solid
tumor cancers, announced today an agreement with the contract manufacturer of its vaccine,
Cognate BioServices, Inc. (Cognate), to convert the $11.6 million of accounts payable to
Cognate into shares of NW Bio common stock at a price of $4.00 per share. These conversions
cover accounts payable from Q4 2012 through July of 2013.
To assure that these shares will not be a factor in the market for an extended period of time, the
Company and Cognate also entered into a lock-up agreement pursuant to which Cognate agreed
to an 18-month lock-up of these conversion shares. Under the lock-up, the shares cannot be sold
or traded.
Cognate has provided manufacturing and regulatory assistance to NW Bio in the US since 2004,
in Israel since 2008 and in Europe since 2010. Cognate is a leading specialist in cellular
products for both immune therapies and regenerative medicine. In addition to manufacturing,
Cognate’s services cover all aspects of product design, manufacturing process design, assay
development (for testing of product potency, composition, etc.), development of Standard
Operating Procedures and other key operating documents, quality control and quality assurance,
cryopreservation processing, multi-year frozen storage and banking, technology transfer and
personnel training, and all aspects of product distribution and logistics to the point of care.
Cognate’s team has been responsible for the product aspects of two dozen INDs (clinical trial
applications), ranging from Phase I through Phase III trials, in both the US and Europe, with
diverse cell types for diverse disease applications, and with all of these INDs approved on first
submission to the respective regulators. Cognate shares common ownership with NW Bio (by
Toucan Capital), and as such is an affiliate of NW Bio under the securities laws.
Cognate’s willingness to provide favorable terms and to accept a substantial portion of its
billings in NW Bio stock has enabled NW Bio to reduce its cash burn while building its 2
operations in Europe as well as the US, and while aggressively pursuing two major clinical
programs (both DCVax-L and DCVax-Direct) simultaneously.
On a going forward basis, NW Bio and Cognate agreed to establish a regular ongoing
arrangement for payment of at least half of each invoice in stock, and the remainder in cash, at
$4.00 per share. The arrangement will continue until terminated by mutual agreement

NWBO

Tengo la duda de si ésta new es buena o mala para el valor...
A mi me da la impresión que es buena, ya que supone la conversión de 11,6M deuda en acciones, correspondiente a las facturas de Q4 de 2012 hasta julio de 2013, y además, el precio fijado de 4$ es superior a los precios actuales...
Además, se pacta que las próximas facturas que COGNATE emita, se pagarán el 50% en cash y el otro 50% en acciones, a razón de 4$ por título.
Se establece una restricción de trading durante 18 meses, para que las nuevas acciones, que serán casi 3 millones, no influyan en el precio.

Un saludo

NWBO

http://www.cognatebioservices.com/index.php?option=com_content&view=article&id=46&Itemid=53

Los 4$ demuestran confianza por parte de la direccion qur el precio ira mas arriba,

Creo que esta parte es vital :
"To assure that these shares will not be a factor in the market for an extended period of time, the
Company and Cognate also entered into a lock-up agreement pursuant to which Cognate agreed
to an 18-month lock-up of these conversion shares. Under the lock-up, the shares cannot be sold or traded"

Eso va a dar una estabilidad al NWBO que no la tendria si Cognate pudiera vender todas las acciones el mismo dia que el valor tocara los 4$. Si he entendido bien, es casi como un pagare con vencimiento a 18 meses.

edito: ya lo habias puesto tú,
creo que es un buen trato

Exacto, y además, supone una forma de fianciación de la empresa sin perjuicio para los accionistas hasta dentro de 18 meses, ya que han cancelado las facturas del Q4 de 2012 y hasta julio de 2013, y en cuanto a las próximas, podrán abonar la mitad de cada una con el mismo sistema de acciones a 4$...

Imagino que mañana va a subir el precio...

Un saludo y gracias por la respuesta...

NWBO